About Spirosure
Spirosure is a company based in Pleasanton (United States) founded in 2011 by Solomon Ssenyange was acquired by CAIRE in June 2020. Spirosure has raised $50 million across 4 funding rounds from investors including Fosun Pharmaceutical, Caireinc and Niterra Ventures. The company has 12 employees as of December 31, 2022. Spirosure operates in a competitive market with competitors including Eversens, Linshom, Apieron, Deep Breath Intelligence and Deversify, among others.
- Headquarter Pleasanton, United States
- Employees 12 as on 31 Dec, 2022
- Founders Solomon Ssenyange
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Spirosure, Inc.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$50 M (USD)
in 4 rounds
-
Latest Funding Round
$15 M (USD), Series C
Jan 08, 2018
-
Investors
Fosun Pharmaceutical
& 7 more
-
Employee Count
12
as on Dec 31, 2022
-
Acquired by
CAIRE
(Jun 03, 2020)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Spirosure
Spirosure has successfully raised a total of $50M across 4 strategic funding rounds. The most recent funding activity was a Series C round of $15 million completed in January 2018. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Spirosure
Spirosure has secured backing from 8 investors, including venture fund and institutional investors. Prominent investors backing the company include Fosun Pharmaceutical, Caireinc and Niterra Ventures.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Innovative ideas are transformed into reality by Niterra Ventures.
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked | |
|
Early-stage sector-agnostic VC firm investing in geographies such as the US
|
Locked | Locked | Locked |
Investor details for Spirosure
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Spirosure
Investment portfolio details for Spirosure
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Spirosure
Detailed financials for Spirosure
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Spirosure Comparisons
Peer comparison for Spirosure
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Spirosure
Spirosure operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Eversens, Linshom, Apieron, Deep Breath Intelligence and Deversify, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Developer of non-invasive diagnostic system to detect bio-markers
|
|
| Locked | Locked | Locked |
Developer of respiratory monitoring devices
|
|
| Locked | Locked | Locked |
Functions as an asthma monitoring device for health management.
|
|
| Locked | Locked | Locked |
AI and mass spectrometry platforms for personalized medicine are developed.
|
|
| Locked | Locked | Locked |
Breath analyzers for acetone concentration in exhaled air are developed.
|
|
| Locked | Locked | Locked |
Non-invasive respiratory measurement devices are developed for gas exchange assessment.
|
Detailed competitors of Spirosure
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Spirosure
Complete news archive for Spirosure
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Spirosure
Spirosure was founded in 2011 and raised its 1st funding round 3 years after it was founded.
Spirosure is headquartered in Pleasanton, United States. It is registered at Pleasanton, California, United States.
Spirosure is a funded company, having raised a total of $50M across 4 funding rounds to date.
As of Dec 31, 2022, the latest employee count at Spirosure is 12.
Spirosure is engaged in the research, development and commercialization of novel breath analysis devices for the diagnosis and management of diseases. The companys current focus is on the non-invasive monitoring and management of chronic pulmonary diseases such as Asthma, COPD, cystic fibrosis, and pulmonary hypertension. Their products include the Fenom PRO POC breathalyzer and the Fenom HOME at-home breathalyzer for measurement of fractional exhaled Nitric Oxide in the management of Asthma.
Spirosure has 8 investors. Key investors include Fosun Pharmaceutical, Caireinc, Niterra Ventures, NGK Spark Plugs, and South Valley Angels.